How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?  

I have had good success with both deucravacitinib and bimekizumab and these agents are two welcome additions to our psoriasis treatment arsenal. For deucravacitinib, ever since I included it in my list of options in treating psoriasis - as an aside, I used to skip over orals due to lack of efficacy...

I’ve begun treating patients with both deucravacitinib and bimekizumab. I tend to prescribe deucravacitinib to patients who prefer oral treatment and who don’t mind the slight herpes simplex/zoster signal associated with the drug. I also use it for patients who have failed multiple biolo...

I have an unusual practice as I treat very severe psoriasis in patients who typically have failed multiple treatments. I've had great success with bimekizumab in some of my hardest-to-treat patients who have failed literally everything else. The question now is, will these patients continue to respo...